Zura Bio Ltd - Class A
Research Zura Bio Ltd - Class A (ZURA) on Bullrun: market cap USD 603.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZURA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 603.07M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 24.22M
- Free cash flow-USD 18.94M
Valuation Snapshot
latest market cap is USD 603.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 68.65M | -USD 64.93M | n/a | -1.06 | USD 109.41M | n/a | USD 101.54M |
| FY2024 | USD 0 | -USD 52.40M | -USD 28.15M | n/a | -0.6 | USD 176.50M | n/a | USD 146.82M |
| FY2023 | n/a | -USD 60.36M | n/a | n/a | -2.09 | USD 99.81M | n/a | USD 59.33M |
| FY2022 | n/a | -USD 25.70M | n/a | n/a | -141.97 | USD 13.79K | n/a | -USD 32.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 603.07M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 386.09M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 163.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 201.25M | n/a | n/a | n/a |
About Zura Bio Ltd - Class A
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zura Bio Ltd - Class A's market cap?
Zura Bio Ltd - Class A's market capitalization is USD 603.07M.
What does Zura Bio Ltd - Class A do?
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.